Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications

Immunotherapy has been well regarded as one of the safer and antigen-specific anti-cancer treatments compared to first-generation chemotherapy. Since Coley’s discovery, researchers focused on engineering novel antibody-based therapies. Including artificial and modified antibodies, such as antibody fragments, antibody-drug conjugates, and synthetic mimetics, the variety of immunotherapy has been rapidly expanding in the last few decades. Genetic and chemical modifications to monoclonal antibody have been brought into academia, in vivo trials, and clinical applications. Here, we have looked around antibodies overall. First, we elucidate the antibody structure and its cytotoxicity mechanisms. Second, types of therapeutic antibodies are presented. Additionally, there is a summarized list of US Food and Drug Administration (FDA)-approved therapeutic antibodies and recent clinical trials. This review provides a comprehensive overview of both the general function of therapeutic antibodies and a few main variations in development, including recent advent with the proposed mechanism of actions, and we introduce types of therapeutic antibodies, clinical trials, and approved commercial immunotherapeutic drugs.

• Publication year

  2021

• Venue

  Molecular Therapy: Oncolytics

• Publication date

  2021-08-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.omto.2021.08.005PMID 34514097PMCID 8416972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nanomaterials for T-cell cancer immunotherapy

  2021cited by this paper
• T cell-engaging therapies — BiTEs and beyond

  2020cited by this paper
• Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

  2020influential reference
• Fueling chimeric antigen receptor T cells with cytokines.

  2020cited by this paper
• FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

  2020influential reference
• PD-1/PD-L1 pathway: current researches in cancer.

  2020cited by this paper
• Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking for Enhanced Adoptive Immunotherapy in Solid Tumors.

  2020cited by this paper
• Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

  2020cited by this paper
• Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

  2020cited by this paper
• Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.

  2020cited by this paper
• Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.

  2020cited by this paper
• FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

  2020cited by this paper
• Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

  2020influential reference
• A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

  2020cited by this paper
• The role of IgG Fc receptors in antibody-dependent enhancement

  2020cited by this paper
• FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

  2020cited by this paper
• Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use

  2020cited by this paper
• Research Progress on NK Cell Receptors and Their Signaling Pathways

  2020cited by this paper
• EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

  2020cited by this paper
• Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report

  2020cited by this paper
• Antibody-Drug Conjugates: The New Frontier of Chemotherapy

  2020cited by this paper
• Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients

  2020cited by this paper
• Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation

  2020influential reference
• The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

  2020cited by this paper
• Targeted Therapy With Immunoconjugates for Multiple Myeloma

  2020cited by this paper
• New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?

  2020cited by this paper
• Live cell imaging of lytic granule motility in anti-ErbB2 CAR NK cells and FcR NK cells plus Herceptin towards ErbB2+ breast cancer cells

  2020cited by this paper
• CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression

  2020cited by this paper
• Phagocytosis: Our Current Understanding of a Universal Biological Process

  2020cited by this paper
• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

  2020cited by this paper
• Regional Injection of CAR-T Cells for the Treatment of Refractory and Recurrent Diffuse Large B Cell Lymphoma: A Case Report

  2020cited by this paper
• The future of cancer immunotherapy: microenvironment-targeting combinations

  2020cited by this paper
• Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

  2019cited by this paper
• Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.

  2019cited by this paper
• Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development.

  2019cited by this paper
• Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

  2019cited by this paper
• Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

  2019cited by this paper
• Immune checkpoint inhibitors: Advances and impact in neuro-oncology

  2019cited by this paper
• Antibody-Drug Conjugates: Possibilities and Challenges

  2019cited by this paper
• Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration

  2019cited by this paper
• RaptRanker: in silico RNA aptamer selection from HT-SELEX experiment based on local sequence and structure information

  2019cited by this paper
• DARPins: Promising Scaffolds for Theranostics

  2019cited by this paper
• Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function.

  2019cited by this paper
• In vivo tumor-suppressing and anti-angiogenic activities of a recombinant anti-CD3ε nanobody in breast cancer mice model.

  2019cited by this paper
• Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

  2019cited by this paper
• Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

  2019cited by this paper
• Bispecific antibodies in cancer immunotherapy.

  2019cited by this paper
• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

  2019cited by this paper
• Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

  2019cited by this paper
• Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

  2019cited by this paper
• The Therapeutic Potential of Nanobodies

  2019cited by this paper
• Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

  2019cited by this paper
• Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors

  2019cited by this paper
• Neoantigen vaccine: an emerging tumor immunotherapy

  2019cited by this paper
• Design and Production of Bispecific Antibodies

  2019cited by this paper
• Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration

  2019cited by this paper
• Crosstalk between cancer and immune cells: Role of tumor‐associated macrophages in the tumor microenvironment

  2019cited by this paper
• Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy

  2019cited by this paper
• Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC).

  2019cited by this paper
• KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe

  2019cited by this paper
• Chimeric antigen receptor T (CAR‐T) cells present with reactive and pleomorphic morphology in bone marrow

  2019cited by this paper
• Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy

  2019cited by this paper
• A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.

  2019cited by this paper
• Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy.

  2019cited by this paper
• NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.

  2019influential reference
• Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients

  2019cited by this paper
• Lung Defenses

  2019cited by this paper
• Targeting Trop-2 in solid tumors: future prospects

  2019cited by this paper
• Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

  2019cited by this paper
• Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses

  2019cited by this paper
• Antibody-Drug Conjugates in Bladder Cancer

  2018cited by this paper
• The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity

  2018cited by this paper
• Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update.

  2018cited by this paper
• Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

  2018cited by this paper
• Engineering and Design of Chimeric Antigen Receptors

  2018influential reference
• Caplacizumab: First Global Approval

  2018cited by this paper
• Humanization of Antibodies using a Statistical Inference Approach

  2018cited by this paper
• Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

  2018cited by this paper
• Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement

  2018cited by this paper
• Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

  2018cited by this paper
• Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

  2018cited by this paper
• Bispecific antibodies: design, therapy, perspectives

  2018cited by this paper
• Prospects of IL-2 in Cancer Immunotherapy

  2018cited by this paper
• Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.

  2017cited by this paper
• Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate

  2017cited by this paper
• The Different Mechanisms of Cancer Drug Resistance: A Brief Review

  2017cited by this paper
• The making of bispecific antibodies

  2017cited by this paper
• MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue

  2017cited by this paper
• Antibody Mimetics, Peptides, and Peptidomimetics.

  2017cited by this paper
• Single-Domain Antibodies As Therapeutics against Human Viral Diseases

  2017cited by this paper
• Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy

  2017cited by this paper
• Complementarity determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv

  2017cited by this paper
• Current clinical trials in non-muscle invasive bladder cancer.

  2017cited by this paper
• Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates

  2017cited by this paper
• Production of complement components by cells of the immune system

  2017cited by this paper
• A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells

  2017influential reference
• Assessment of disulfide and hinge modifications in monoclonal antibodies

  2017cited by this paper
• Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.

  2017cited by this paper
• Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead

  2017cited by this paper
• Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics

  2017cited by this paper

• Two-in-one protein tag enables the soluble expression and calcium-dependent purification of single-chain antibody fragments

  2026cites this paper
• Novel human single-domain antibodies exert potent anti-tumor activity by targeting EGF-like repeat epitope of EpCAM

  2025cites this paper
• Serum autoantibody-based biomarkers for prognosis in early-stage lung cancer patients with surgical resection

  2025cites this paper
• In vitro anti-tumor activities of a novel recombinant immunotoxin targeting differentially overexpressed Leucine-rich repeat-containing G-protein-coupled receptor 5 in cervical cancer

  2025cites this paper
• Cell Surface Markers of Mesenchymal Stem Cells: Current Knowledge and Advances in Characterization Technologies

  2025cites this paper
• Technological advancements in antibody-based therapeutics for treatment of diseases

  2025cites this paper
• Monoclonal antibodies: From magic bullet to precision weapon

  2024cites this paper
• Construction of a versatile fusion protein for targeted therapy and immunotherapy

  2024cites this paper
• Accelerating drug discovery, development, and clinical trials by artificial intelligence.

  2024cites this paper
• A glycosylation-related signature predicts survival in pancreatic cancer

  2023cites this paper
• Development of a validated molecular analytical method to determine the viral safety of F(AB´)2 products: A novel application for a well-known technique

  2023cites this paper
• The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

  2023cites this paper
• Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.

  2023cites this paper
• Mucosal absorption of antibody drugs enhanced by cell-penetrating peptides anchored to a platform of polysaccharides.

  2023cites this paper
• Exploiting the Features of Short Peptides to Recognize Specific Cell Surface Markers

  2023cites this paper
• Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies

  2023cites this paper
• Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention

  2022cites this paper
• Autoantibody panel on small extracellular vesicles for the early detection of lung cancer.

  2022cites this paper
• Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients

  2022cites this paper
• The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment

  2022cites this paper
• A Novel Pyroptosis-Related Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Osteosarcoma

  2021cites this paper
• Applying Synthetic Biology with Rational Design to Nature’s Greatest Challenges: Bioengineering Immunotherapeutics for the Treatment of Glioblastoma

  2021cites this paper